8-K: ImmuCell and Norbrook Amend Supply Agreement, Set Termination Date for 2026

ImmuCell Corporation and Norbrook Laboratories Limited have amended their supply agreement, setting a termination date of March 31, 2026, for their collaboration on Re-Tain.

Summary

• ImmuCell Corporation has entered into an amending agreement with Norbrook Laboratories Limited.
• This amendment modifies their existing Development Services and Commercial Supply Agreement, originally dated September 5, 2019.
• Norbrook provides formulation, aseptic filling, and packaging services for ImmuCell's Re-Tain product, a treatment for subclinical mastitis in dairy cows.
• The key change is that the agreement will now terminate on March 31, 2026.
• Norbrook will complete the manufacture of current in-process inventory before the termination date.
• If FDA approval for the product is not received by ImmuCell by February 28, 2026, the agreement will expire on March 31, 2026.
• Upon expiry, Norbrook will invoice ImmuCell for the final balance due.

Sentiment

Score: 5

Explanation: The document is neutral, outlining a contractual change with both potential risks and a clear timeline. It is not overly positive or negative.

Positives

• The amendment provides a clear timeline for the conclusion of the agreement.
• Norbrook will complete the manufacture of current in-process inventory, ensuring no immediate disruption to supply.
• The agreement specifies the process for final payment upon termination.

Negatives

• The agreement's termination in 2026 could impact the long-term supply of Re-Tain.
• The agreement's termination is linked to FDA approval by February 28, 2026, creating a potential risk if approval is delayed.

Risks

• Failure to obtain FDA approval for Re-Tain by February 28, 2026, will result in the termination of the agreement.
• ImmuCell will need to find an alternative manufacturing partner for Re-Tain after March 31, 2026, if they wish to continue production.
• The termination of the agreement could lead to supply chain disruptions.

Future Outlook

The agreement will terminate on March 31, 2026, unless FDA approval for Re-Tain is not received by February 28, 2026, in which case the agreement will expire on March 31, 2026. ImmuCell will need to secure a new manufacturing partner if they wish to continue production of Re-Tain after this date.

Management Comments

• Michael F. Brigham, President and CEO of ImmuCell, signed the amending agreement on behalf of the company.

Industry Context

This agreement is specific to the manufacturing of ImmuCell's Re-Tain product. The termination of the agreement highlights the importance of securing reliable manufacturing partners in the pharmaceutical industry, particularly for products requiring FDA approval.

Comparison to Industry Standards

• Contract manufacturing agreements are common in the pharmaceutical industry, with companies often relying on third-party manufacturers for production.
• The termination clause linked to FDA approval is not unusual, as regulatory hurdles can significantly impact product timelines.
• Companies like Catalent and Lonza are major players in contract manufacturing, and ImmuCell may need to explore similar partnerships in the future.

Stakeholder Impact

• Shareholders may be concerned about the potential disruption to Re-Tain supply.
• Employees involved in the Re-Tain product line may be affected by the change in manufacturing.
• Customers relying on Re-Tain may need to be informed of potential changes in supply.

Next Steps

• ImmuCell needs to secure FDA approval for Re-Tain by February 28, 2026.
• ImmuCell will need to find a new manufacturing partner for Re-Tain if they wish to continue production after March 31, 2026.

Key Dates

Keywords

ImmuCell, Norbrook, Re-Tain, Supply Agreement, Manufacturing, FDA Approval, Mastitis, Termination, Pharmaceuticals, Dairy